Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 11/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536709 | 0.89 | HDAC1 (0.54) | HDAC1LMNAHDAC11HDAC8HDAC6 | |
| SCHEMBL8264169 | 0.86 | HDAC1 (0.41) | HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL3534436 | 0.80 | HDAC1 (0.64) | MPOHDAC1APOBEC3GKDM4E | |
| SCHEMBL3543942 | 0.78 | HDAC1 (0.49) | HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL3543646 | 0.77 | HDAC1 (0.51) | HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL3534490 | 0.77 | HDAC1 (0.57) | HDAC1LMNAALDH1A1HDAC11HDAC8 | |
| SCHEMBL6075959 | 0.73 | HDAC1 (0.51) | HDAC1MAPTHDAC11HDAC8HDAC6 | |
| SCHEMBL3556616 | 0.73 | HDAC1 (0.42) | HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL3534119 | 0.73 | HDAC1 (0.52) | HDAC1KDM4EHDAC11HDAC8HDAC6 | |
| SCHEMBL23997215 | 0.70 | CYP1A2 (0.48) | HDAC1KDM4ELMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824831-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | claimed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1824831-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205941-A1 | Histone deacetylase inhibitors | HDAC1, HDAC3, HDAC5 | MPO 414/4885HDAC1 1/4885APOBEC3G 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.